UK Claims World First With ‘Point Of Care’ Manufacturing Rules
MHRA Says New Rules Will Increase Availability Of Innovative New Products
Executive Summary
The MHRA says its proposals for a new, tailormade regulatory regime for personalized medicines manufactured at the point of care are evidence of its “intent to move away from a common perception of regulators as a progress blocker to a progress enabler.”
You may also be interested in...
How Industry Would Reduce The Regulatory Burden For Fleets Of Mobile Manufacturing Units
Stakeholders propose centralized oversight approaches for managing quality of “like-for-like” fleets of self-contained manufacturing units that could roam the US – or the world. The US FDA shares the industry’s thinking on how best to adapt the site-focused regulatory scheme it enforces to the emerging variety of distributed manufacturing systems.
Twenty Questions: How Should The US FDA Regulate Distributed Drug Manufacturing?
What happens when manufacturing plants are moving targets? When quality systems are at once more centralized and dispersed? When plant operators are health care workers? Agency wants input before settling on the answers.
Industry Urged To Share Potential Regulatory Challenges To Decentralized Manufacturing
In a world where pharmaceuticals could be manufactured with no fixed address, industry and regulatory authorities must work together to interpret site-based compliance requirements, expert says. New concepts like the MHRA-proposed hub-and-spokes model could play key role.